Navigation Links
Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
Date:10/1/2013

ster Hall Interferon-Free Treatment with

Faldaprevir, Deleobuvir (BI 207127)

and Ribavirin in SOUND-C3: 95% SVR12

in HCV-GT1b

J.F. Dufour

ID# 1102
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall STARTVerso 4 Phase III trial of

faldaprevir plus peg interferon alfa-2a

and ribavirin (PR) in patients with HIV

and HCV genotype 1 coinfection:

end of treatment response

J. Rockstroh

ID# 1099
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall Pharmacokinetic interactions of

Faldaprevir and Deleobuvir (BI 207127)

and their individual and combined effect on

selected cytochrome P450 (CYP) probe

substrates in genotype 1 hepatitis C

infected patients

C. Cooper

ID# 1083
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso and HCVerso®.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso is a multi-study Phase 3 trial program that evaluates faldaprevir combined with PegIFN/RBV. The four trials that make up this program study
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
2. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
3. CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
4. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
5. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
6. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
9. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
10. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
11. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BOSTON , September 16, 2014 ... Fiona Marshall , will give a presentation entitled " ... StaR ®   technology " ... and Development " virtual symposium run by Chemical & Engineering ... symposium is on Wednesday, 24 September 2014; Dr Marshall,s presentation ...
(Date:9/15/2014)... FRANCISCO , Sept. 15, 2014 ... studies presented at the American Society for Radiation ... its Decipher® Prostate Cancer Classifier, a genomic test ... influence treatment decisions and improve patient outcomes for ... These presentations follow a recently published study that ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data on the ... report provides value, in millions of US dollars, ... dollars) within market segments Invasive Body Contouring Devices ... Radio Frequency-Assisted Liposuction (RFAL) Devices, Ultrasound-Assisted Liposuction (UAL) ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5
... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... emerging leader in the development, assembly, marketing and sale ... today announced that it was granted three new patents ... of China ("SIPO"). The patent awards were related to ...
... Cellular Dynamics International (CDI) today announced the online publication ... demonstrating for the first time a methodology for researchers ... blood samples through the creation of induced pluripotent stem ... B-cell lines reprogrammed to EBV-free induced pluripotent stem cells," ...
Cached Medicine Technology:Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2
(Date:9/16/2014)... Discussion abstracts to be presented at the ESMO 2014 ... 2014 at 12:00 (CEST) to give you a first ... medical oncology Congress, under the leading theme Precision Medicine ... where genuinely targeted therapy is now possible for an ... are all working towards a common goal --improved patient ...
(Date:9/16/2014)... Perkins, OK (PRWEB) September 16, 2014 ... Superfood, rich in iron and potassium. They are ... high nutritional values and their healing and health ... and meaty texture Shiitakes can stimulate and strengthen ... infections. Shiitakes contain polycharrides, including beta ...
(Date:9/16/2014)... Atlanta, GA (PRWEB) September 16, 2014 ... cloud-based clinical, business management and billing software solutions ... immediate availability of its latest release of ... providers, orthotics and prosthetics providers as well as ... for prior authorization requests (PARs), electronic purchasing, document ...
(Date:9/16/2014)... Albany, New York (PRWEB) September 16, 2014 ... intelligence firm states that the global facial care market ... billion by 2019. The report, titled ‘Facial Care Market ... Facial Creams, Face Wash, Cleansing Wipes, Serums and Masks ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 ...
(Date:9/16/2014)... Cloud based mobile app builder Appy ... API’S to serve m3u8 streams on Android & iOS. ... video events with hundreds of thousands of simultaneous viewers ... is known for making beautiful and interactive apps for ... 8 and already over 100,000 apps have passed through ...
Breaking Medicine News(10 mins):Health News:ESMO 2014 Congress Preview 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3Health News:Brightree Announces Availability of Latest Release 2Health News:Brightree Announces Availability of Latest Release 3Health News:Brightree Announces Availability of Latest Release 4Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... their seatbelts than the rest of the population, adding ... growing problem. , The connection was made by ... Meharry Medical College in Nashville, Tenn. , We found ... Schlundt, associate professor of psychology and assistant professor of ...
... as a non-invasive way to determine the existence and ... development of pharmacologic strategies to combat the condition. These ... journal published by John Wiley & Sons on behalf ... Diseases (AASLD). The article is also available online at ...
... two editorials published in the September 2007 issue ... medical ethicist discussed whether doctors should participate in ... discussions about physician involvement in capital punishment have ... court systems. And the North Carolina Medical Board ...
... Commissioner Dr. Thomas R. Frieden, and Consumer Affairs Commissioner Jonathan ... City Youth Risk Behavior Survey (YRBS) showing that cigarette smoking ... 2005 and 2007. The citys teen smoking rate has dropped ... 17.6 percent in 2001 to 8.5 percent in 2007. The ...
... BOSTON, Mass. (Jan. 2, 2008) Athanasios Zavras began ... reports linked oral osteoporosis meds to bone death in ... women and men taking these drugs to postpone dental ... exacerbate the problem. Thats when Zavras, an associate professor ...
... misguided zealots are promoting numerous stress reduction devices, ... The vast majority are supported only by ... others. Very often, as in the case ... stress, scholarly articles from prestigious journals are cited ...
Cached Medicine News:Health News:Obesity linked to decreased seatbelt use 2Health News:MRI techniques evolving towards better assessment of liver fibrosis 2Health News:Mayo Clinic Proceedings provides forum for debate about capital punishment 2Health News:Mayo Clinic Proceedings provides forum for debate about capital punishment 3Health News:Smoking rate among New York City teens was lowest on record in 2007 2Health News:Smoking rate among New York City teens was lowest on record in 2007 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: